Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-058806
Filing Date
2025-04-25
Accepted
2025-04-25 16:39:31
Documents
17
Period of Report
2025-04-25

Document Format Files

Seq Description Document Type Size
1 DEF 14A janx-20250424.htm   iXBRL DEF 14A 1081916
2 GRAPHIC img113466067_0.jpg GRAPHIC 14300
3 GRAPHIC img113466067_1.jpg GRAPHIC 143287
4 GRAPHIC img113466067_2.jpg GRAPHIC 185386
5 GRAPHIC img113466067_3.jpg GRAPHIC 1172112
6 GRAPHIC img113466067_4.jpg GRAPHIC 694525
  Complete submission text file 0000950170-25-058806.txt   7497592

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT janx-20250424.xsd EX-101.SCH 7930
19 EXTRACTED XBRL INSTANCE DOCUMENT janx-20250424_htm.xml XML 206502
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40475 | Film No.: 25874790
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)